Hans-Jorg Senn H.-J. Senn (~) Center for Tumor Detection and Prevention, Rorschacherstr. 150, CH-9006 St. Gallen, Switzerland Clinical oncology has centered mainly on developing new strategies and a multitude of new drugs for fighting relapsing and progressive cancer during the last two decades. Furthermore, it has done this with respectable success in quite a number of neoplastic diseases such as acute leukemias and sarcomas in pediatric patients and certain types of aggressive lymphomas, as well as se lected solid tumors such as testicular cancer and choriocarcinoma in adult age. Curatively intended adjuvant chemo-and endocrine-therapies of several "main killers" among prevalent cancer types, especially breast and colon can cer, have also become successful and health-politically meaningful therapeutic targets [1, 2]. However, the net gain in "cure" of these (mostly pharmacologic) therapeu tic approaches has to be realistically judged as having a moderate impact on the cancer problem as a whole, and the mortality rate of the most frequent tu mor types, which are prevalent in adult life, has with very few exceptions not been substantially decreased over the past two to three decades. Increasingly, health politicians, epidemiologists, and medical journal editors are asking for alternative strategies of lowering cancer incidence and increasing survival, ventilating new and hitherto mostly neglected areas of research such as pri mary and secondary cancer prevention.
Erscheinungsdatum: 08.10.2012

lgli/R:\062020\springer2\10.1007%2F978-3-642-55647-0.pdf

lgrsnf/R:\062020\springer2\10.1007%2F978-3-642-55647-0.pdf

nexusstc/Tumor Prevention and Genetics/b0474dd04dc5e8e779470e1b1a93eea5.pdf

scihub/10.1007/978-3-642-55647-0.pdf

zlib/Medicine/Hans-Jörg Senn (auth.), Prof Dr. Hans-Jörg Senn, Dr. Rudolf Morant (eds.)/Tumor Prevention and Genetics_5923193.pdf

Hans-Jörg Senn, Rudolf Morant, Hans-J\xf6rg Senn

Hans-J\xf6rg Senn, Rudolf Morant

Spektrum Akademischer Verlag. in Springer-Verlag GmbH

Steinkopff. in Springer-Verlag GmbH

Springer London, Limited

Springer Nature

Recent results in cancer research, 163, Berlin, Heidelberg, 2003

Softcover reprint of the original 1st ed. 2003, 2012

Springer Nature, Berlin, Heidelberg, 2012

Germany, Germany

Oct 08, 2012

1, 20121206

lg2757799

producers:
Adobe Acrobat 9.43 Paper Capture Plug-in

{"container_title":"Recent Results in Cancer Research","edition":"1","isbns":["3642556477","3642628923","9783642556470","9783642628924"],"issns":["0080-0015"],"last_page":266,"publisher":"Springer","series":"Recent Results in Cancer Research 163"}

Source title: Tumor Prevention and Genetics (Recent Results in Cancer Research)

Front Matter....Pages I-VII
Introduction....Pages 1-3
Front Matter....Pages 5-5
Genetic Susceptibility, Predicting Risk and Preventing Cancer....Pages 7-18
Novel Approaches to Identify Low-Penetrance Cancer Susceptibility Genes Using Mouse Models....Pages 19-27
Front Matter....Pages 29-29
Development of Novel Selective Cell Ablation in the Mammary Gland and Brain to Study Cell-Cell Interactions and Chemoprevention....Pages 31-45
Mouse Skin as a Model for Cancer Chemoprevention by Nonsteroidal Anti-Inflammatory Drugs....Pages 46-57
Preclinical Models for Chemoprevention of Colon Cancer....Pages 58-71
New Cancer Biomarkers Deriving from NCI Early Detection Research....Pages 72-84
Front Matter....Pages 85-85
Tamoxifen’s Impact as a Preventive Agent in Clinical Practice and an Update on the STAR Trial....Pages 87-95
Aromatase Inhibitors in Prevention — Data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial and the Design of IBIS-II (the Second International Breast Cancer Intervention Study)....Pages 96-103
HRT Opposed to Low-Dose Tamoxifen (HOT Study): Rationale and Design....Pages 104-111
Front Matter....Pages 113-113
Is Mammography Screening for Breast Cancer Really Not Justifiable?....Pages 115-128
How Reliable Is the Evidence for Screening Mammography?....Pages 129-139
Political Interpretation of Scientific Evidence — Case Study of Breast Cancer Screening Policies Around the World....Pages 140-148
Front Matter....Pages 149-149
Skin Cancer Chemoprevention: Strategies to Save Our Skin....Pages 151-164
Chemoprevention of Nonmelanoma Skin Cancer: Experience with a Polyphenol from Green Tea....Pages 165-171
Chemoprevention of Lung Cancer: New Directions....Pages 172-181
Key Issues in Lung Cancer Chemoprevention Trials of New Agents....Pages 182-195
Front Matter....Pages 197-197
Prevention of Prostate Cancer....Pages 199-211
Clinical Models for Testing Chemopreventative Agents in Prostate Cancer and Overview of SELCT: The Selenium and Vitamin E Cancer Prevention Trial....Pages 212-225
Problems with Prostate-Specific Antigen Screening: A Critical Review....Pages 226-231
Front Matter....Pages 233-233
Genetic Predisposition as a Basis for Chemoprevention, Surgical and Other Interventions in Colorectal Cancer....Pages 235-247
Fecal Occult Blood Screening — Trial Evidence, Practice and Beyond....Pages 248-253
Is FOB Screening Really the Answer for Lowering Mortality in Colorectal Cancer?....Pages 254-263
Summary and Conclusions....Pages 264-266

This book presents a comprehensive update of the latest findings in oncogenetics. It also investigates the relevance of preclinical models with respect to clinical cancer prevention (primary and secondary) for major cancer types such as breast, skin, lung, prostate and colon cancer. All contributions have been written by internationally recognised experts in the field

2020-08-30